Hepatect Cp (Human Hepatitis B Immunoglobulin)

Hepatect Cp is a prescription immunoglobulin product containing human hepatitis B immune globulin as its active ingredient. It is supplied in an intravenous dosage form and is marketed in the European Union. The preparation provides passive immunity by delivering anti‑hepatitis B surface antigen antibodies, which can neutralize hepatitis B virus and help prevent infection of liver cells. It is used under medical supervision for specific prophylactic indications.

Hepatect Cp is indicated for specific situations where rapid protection against hepatitis B virus is required.

- Prophylaxis after accidental percutaneous or mucosal exposure to hepatitis B infected blood or body fluids. - Prevention of mother‑to‑child transmission when the newborn has not received hepatitis B vaccine at birth. - Prevention of hepatitis B recurrence in patients undergoing liver transplantation. - Post‑exposure prophylaxis for individuals who are non‑immune and have been exposed to hepatitis B. - Supplementary protection for patients with chronic liver disease who are at high risk of hepatitis B infection.

The safety profile of Hepatect Cp reflects the typical reactions observed with human immunoglobulin products administered intravenously.

Common: - Mild fever, chills, or rigors occurring during or shortly after the infusion. - Headache, nausea, or transient abdominal discomfort that resolves without intervention. - Localized infusion‑site reactions such as erythema, swelling, or a brief feeling of warmth.

Serious: - Severe hypersensitivity reactions including anaphylaxis, characterized by respiratory distress, urticaria, or hypotension. - Aseptic meningitis presenting with headache, neck stiffness, and photophobia after infusion. - Renal impairment or hemolysis indicated by reduced urine output, elevated creatinine, or hemoglobinuria.

When using Hepatect Cp, clinicians should consider several precautionary measures to ensure patient safety.

- Assess patient’s immunoglobulin tolerance and history of allergic reactions before infusion. - Monitor vital signs and observe for signs of hypersensitivity during the first 30 minutes of administration. - Adjust dosage or infusion rate in patients with renal insufficiency or cardiovascular disease. - Avoid use in individuals with known IgA deficiency who have anti‑IgA antibodies. - Ensure hepatitis B vaccination status is documented; Hepatect Cp does not replace active immunization. - Use caution in pregnant or breastfeeding women; limited safety data are available.

Hepatect Cp may interact with other medications or clinical conditions, requiring attention to avoid adverse outcomes.

Avoid: - Concurrent administration of other blood‑derived products (e.g., plasma, albumin) without appropriate monitoring. - Live vaccines administered within 4 weeks of Hepatect Cp infusion.

Use with caution: - Immunosuppressive agents such as corticosteroids or biologics that may alter immune response. - Anticoagulants, because rapid infusion can affect coagulation parameters. - Diuretics or nephrotoxic drugs in patients with compromised renal function.